Physician profile
Noah C Bourne
NPI 1194508002
$7,476.99
in general payments reported to CMS, 2019-2025
29 companies · $3,352 in 2025
The $3,352 reported for 2025 was more than what 97% of Adult Health (Nurse Practitioner) providers received nationally (typical 2025 total: $182).
Payments by year
General payments by program year, as reported to CMS.
General payments by year: 2023: $896 · 2024: $3,229 · 2025: $3,352.
What the payments were for
Nature of payment as categorized by the reporting companies: meals, consulting, travel, and so on.
Food and Beverage: $7,477.
View as a table
| Payment type | Amount (2023-2025) |
|---|---|
| Food and Beverage | $7,476.99 |
Payment-type detail covers 2023-2025; earlier years are included in totals but not broken out here.
Who reported paying
General payments only, as reported to CMS. Product names cover 2023-2025.
| Company | General payments | Years | Top products |
|---|---|---|---|
| Amgen INC. | $1,827.44 | 2023-2025 | Krystexxa, Uplizna, Evenity |
| Abbvie INC. | $1,270.88 | 2023-2025 | |
| Astrazeneca Pharmaceuticals LP | $861.73 | 2023-2025 | Saphnelo |
| Ucb, INC. | $563.03 | 2024-2025 | Bimzelx, Cimzia |
| Pfizer INC. | $318.22 | 2023-2025 | |
| Boehringer Ingelheim Pharmaceuticals, INC. | $263.02 | 2024-2025 | Ofev |
| Janssen Biotech, INC. | $192.84 | 2023-2025 | Tremfya |
| E.R. Squibb & Sons, L.L.C. | $164.81 | 2023-2025 | Orencia |
| Novartis Pharmaceuticals Corporation | $150.26 | 2024-2025 | |
| Csl Behring | $145.90 | 2024 | Hizentra |
| Abiomed | $145.40 | 2025 | |
| Janssen Pharmaceuticals, INC | $136.56 | 2024 | Spravato |
| Incyte Corporation | $124.99 | 2023 | Jakafi |
| Novo Nordisk INC | $124.99 | 2025 | Wegovy |
| Phathom Pharmaceuticals, INC. | $124.99 | 2024 | Voquezna |
Show all 29 companies
| Company | General payments | Years | Top products |
|---|---|---|---|
| Mylan Specialty L.P. | $124.99 | 2024 | Yupelri |
| Grifols USA, LLC | $120.18 | 2024 | Prolastin-C Liquid |
| Gilead Sciences, INC. | $119.99 | 2024 | Epclusa |
| Neurelis, INC. | $117.44 | 2024 | Valtoco |
| Corcept Therapeutics | $111.38 | 2025 | Korlym |
| Biogen, INC. | $100.00 | 2023 | Spinraza |
| Alexion Pharmaceuticals, INC. | $82.13 | 2024-2025 | Strensiq |
| Sobi, INC | $58.48 | 2024-2025 | |
| Daiichi Sankyo INC. | $52.82 | 2024 | Injectafer |
| Fresenius Kabi USA, LLC | $50.99 | 2025 | |
| Otsuka Pharmaceutical Development & Commercialization, INC. | $48.15 | 2025 | |
| Invivyd INC | $34.34 | 2025 | Pemgarda |
| Glaxosmithkline, LLC. | $22.74 | 2025 | Benlysta |
| Bioventus LLC | $18.30 | 2025 | Durolane |
Drugs and devices associated with these payments
CMS records which products a payment was associated with, not how the money was allocated. Association is not allocation: one payment can be associated with several products, and a product listing does not mean the payment was made because of that product. Product detail covers 2023-2025.
If you want to bring it up
Most clinicians are glad to talk about this. A respectful way in:
- "I saw Noah Bourne listed in the CMS Open Payments database. Can you tell me about your work with those companies?"
- "Is there a generic or alternative to this medication, and would it work as well for me?"
- "What made you choose this particular treatment for my situation?"
These are normal questions. A good clinician will welcome them.
Share this page
Keep an eye on this page
Get an email when the next June refresh changes this page. No account needed.
Source: CMS Open Payments, program years 2019-2025, as reported to CMS by drug and device makers (published June 30, 2026). Drug and device detail covers 2023-2025.